Foghorn Therapeutics (FHTX) Share-based Compensation (2019 - 2026)

Foghorn Therapeutics' Share-based Compensation history runs 8 years deep, the most recent figure standing at $2.4 million for Q1 2026.

• In Q1 2026, Share-based Compensation fell 11.48% year-over-year to $2.4 million; the TTM figure through Mar 2026 stood at $10.1 million (down 11.19% YoY), while the FY2025 annual figure was $10.4 million, down 12.56% from the prior year.
• Share-based Compensation for Q1 2026 stood at $2.4 million, up from $2.2 million in the prior quarter.
• The five-year high for Share-based Compensation was $4.6 million in Q1 2023, with the low at $2.2 million in Q4 2025.
• The 5-year median for Share-based Compensation is $3.2 million (2024), against an average of $3.2 million.
• The sharpest annual moves came in 2022 and 2024: Share-based Compensation soared 81.43% in 2022, then declined 29.48% in 2024.
• Foghorn Therapeutics' Share-based Compensation stood at $3.8 million in 2022, then dropped by 19.31% to $3.1 million in 2023, then dropped by 18.62% to $2.5 million in 2024, then retreated by 9.75% to $2.2 million in 2025, then gained by 6.34% to $2.4 million in 2026.
• Business Quant data shows FHTX's Share-based Compensation at $2.4 million in Q1 2026, $2.2 million in Q4 2025, and $2.7 million in Q3 2025.